Navigation Links
AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
Date:6/8/2009

All amounts are in US dollars

QUEBEC CITY, June 8 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that after regaining from Ardana Biosciences Ltd. ("Ardana"), the worldwide rights to the growth hormone secretagogue ("GHS") / ghrelin agonist, AEZS-130, it has entered into an agreement with the administrators of Ardana to acquire all Ardana assets relating to AEZS-130 for $232,000. These assets include development data, inventory of compound, regulatory authorizations, including IND and orphan drug status as a diagnostic test granted in the United States, as well as a patent application protecting the use of AEZS-130 for the diagnostic of growth hormone secretion deficiency.

Ardana had developed AEZS-130 up to the initiation of Phase 3 clinical trials in the United States for use as an oral diagnostic test of growth hormone secretion deficiency. In addition to the diagnostic indication, AEZS-130, based on results of Phase 1 studies conducted by Ardana, has potential applications for the treatment of cachexia, a condition frequently associated with severe chronic diseases such as cancer, Chronic Obstructive Pulmonary Disease and AIDS.

"We are pleased to gain access to a project in an advanced development stage," said Juergen Engel, Ph.D., President and CEO of AEterna Zentaris. "Our product portfolio is now complemented with an additional project in Phase 3 clinical trials. We are confident that we can retain the interest of potential strategic partners for this project as we have already initiated partnering discussions."

AEZS-130 Poster Presentation at ENDO

The poster #P2-749 entitled, "Use of an oral GHS ghrelin-mimetic GHS as a simple diagnostic test for adult GH deficiency", G.R. M
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
2. AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting
3. AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
4. AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
5. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
6. AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting
7. AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
8. AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
9. AEterna Zentaris to Announce Fourth Quarter and Full-Year 2008 Financial and Operating Results on March 11, 2009
10. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
11. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading provider ... Limited, one of India’s top five pharmaceutical companies, has ... for high throughput solid form screening. , ... wide range of quality, affordable generic and branded formulations ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have ... at 2pm EST (11am PST), “Natural Language Processing: Converting ... how technology can turn raw, heterogeneous data into actionable ... The online webinar will last approximately one hour. , ...
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
(Date:1/14/2014)... In recent years, growing suspicion about ... product development and promotion has led to unprecedented levels ... by concerns about the insidious impact of commercialization of ... fines to the world’s biggest pharmas for illegal marketing ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... , , HONG KONG, Dec. 31 /PRNewswire-Asia-FirstCall/ ... CO ), China,s leading provider of cord blood ... storage services, today announced that the underwriters of its recent ... their over-allotment option, which will result in the issuance of ...
... NORTH BILLERICA, Mass., Dec. 29 Seahorse Bioscience, Inc., leader ... bioenergetics, announced that TheScientist magazine cited their XF96 ... A panel of scientific experts assembled by TheScientist ... the two energy pathways of the cell in a microplate, ...
... , EMERYVILLE, Calif., Dec. 29 ... of results from its study on the anti-tumor mechanism of ... International Journal of Cancer , describe the potential molecular ... BN107 on estrogen receptor negative (ER-) breast cancer cells. , ...
Cached Biology Technology:China Cord Blood Corporation Announces Partial Exercise of Over-Allotment Option 2China Cord Blood Corporation Announces Partial Exercise of Over-Allotment Option 3TheScientist Awards Seahorse XF96 Analyzer a Top Ten Innovation for 2009 2Bionovo Announces Publication Describing First Novel Dual mTOR Inhibitor, BN107, for the Treatment of Breast Cancer 2Bionovo Announces Publication Describing First Novel Dual mTOR Inhibitor, BN107, for the Treatment of Breast Cancer 3
(Date:4/20/2014)... and pancreatic cancers also promote drug-resistance and ultimately spur ... Diego School of Medicine have discovered a molecule, or ... that appears responsible for inducing tumor metastasis by enhancing ... The findings, published in the April 20, 2014 online ... to new therapeutic opportunities for reversing drug resistance in ...
(Date:4/18/2014)... in Peru found that 28 percent of the ... falsified. Many pills released the active ingredient too ... batch had no active ingredient at all. ... the Georgia Institute of Technology developed a sophisticated ... counterfeit drugs and then characterize their chemical composition. ...
(Date:4/18/2014)... NC Ancient DNA adds a twist to the story ... to be published April 21 in the journal Proceedings ... from the bones of chickens that lived 200-2300 years ago ... ago domestic chickens may have looked far different from the ... of the traits we associate with modern domestic chickens -- ...
Breaking Biology News(10 mins):Cancer stem cells linked to drug resistance 2Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Ancient DNA offers clues to how barnyard chickens came to be 2
... Jianmin Cui was handed a puzzling clue to the structure ... five years. Scientists at the Cleveland Clinic Foundation in ... epilepsy, sudden attacks of involuntary movement or both, a syndrome ... the DNA of the 16 family members who had inherited ...
... are fostering development of a new generation of vaccines, ... potentially deadly bacteria in any future bioterrorist incident. That,s ... on medical technology to combat the anthrax threat. It ... . In the article, Dimitrios Bouzianas notes ...
... Scientists are reporting that particle size affects the toxicity ... smaller than 100 nanometers are slightly more toxic to colon ... toxic than equivalent amounts of soluble zinc, and direct particle ... study is in ACS, Chemical Research in Toxicology , ...
Cached Biology News:Solving the puzzle of the BK ion channel 2Solving the puzzle of the BK ion channel 3Solving the puzzle of the BK ion channel 4Solving the puzzle of the BK ion channel 5New medical weapons to protect against anthrax attacks 2
... for your specific applications and built on ... platform. Thousands of customer specified sequences can ... provide assistance with custom sequence design. These ... comprehensive Custom DNA Microarray Service. ...
... designed for DNA aptamer screening and binding ... powerful Paraflo microfluidic on-chip synthesis platform. These ... comprehensive DNA/RNA Aptamer Microarray Service. ... Microarray contains greater than 1500 known aptamer ...
... for DNA aptamer screening and binding optimization ... Paraflo microfluidic on-chip synthesis platform. Thousands of ... and LC Sciences can provide assistance with ... as part of our comprehensive DNA/RNA Aptamer ...
... (GST) is commonly used as a fusion ... (1). The GSTTag sequence has been reported ... cases the solubility of its fusion partners. ... form, GSTTag fusion proteins can be purified ...
Biology Products: